<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363325">
  <stage>Registered</stage>
  <submitdate>21/12/2012</submitdate>
  <approvaldate>10/01/2013</approvaldate>
  <actrnumber>ACTRN12613000027718</actrnumber>
  <trial_identification>
    <studytitle>Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double-blind, placebo-controlled trial.</studytitle>
    <scientifictitle>Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double-blind, placebo-controlled trial.</scientifictitle>
    <utrn>nil</utrn>
    <trialacronym>nil</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>polycystic ovary syndrome</healthcondition>
    <healthcondition>subfertility</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>standard preparation metformin, 500mg, orally, three times per day (TDS) and clomiphene citrate 25mg-150mg (dose determined by treating clinician), orally, daily.  Clomiphene citrate was administered from day 3-7 of the menstrual cycle.  Metformin was administered daily continuously or until pregnancy was confirmed via a beta-hcg.</interventions>
    <comparator>placebo tablet (identical to metformin but without the active ingredient), orally, three times per day (TDS) and clomiphene citrate 25mg-150mg (dose determined by treating clinician), orally, daily.  Clomiphene citrate was administered from day 3-7 of the menstrual cycle.  The Placebo was administered daily continuously or until pregnancy was confirmed via a beta-hcg.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>ovulation</outcome>
      <timepoint>Ovulation was defined by a serum progesterone measurement &gt; 10.6 nmol/l on either day 21-23 or day 28-30 of the participants menstrual cycle</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>chemical pregnancy</outcome>
      <timepoint>Chemical pregnancy was defined as Beta-hCG &gt; 5 IU/l between days 28-30 or in the case of late ovulation (luteal phase progesterone between days 28-30) between days 35-37 of the participants menstrual cycle</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>live birth documented in the patients medical records by a medical practitioner </outcome>
      <timepoint>once chemical pregnancy was confirmed participants were followed up throughout the course of the trial</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>miscarriage confirmed by a doctor resulting in a beta-hcg &lt;5IU/L</outcome>
      <timepoint>once chemical pregnancy was confirmed participants were followed up throughout the course of the trial</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>women with polycystic ovary syndrome, desiring pregnancy, with subfertility</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Women were excluded from the study if they had other causes of anovulation (specifically hyperprolactinaemia, hypothyroidism and congenital adrenal hyperplasia), diabetes mellitus or if the semen analysis of their partner indicated male factor subfertility</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>participants were recruited from the Royal Brisbane and Women's Hospital Gynaecology outpatient department.  Allocation was double blinded and executed by the hospital pharmacy department.</concealment>
    <sequence>random computer generated sequence</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>False</masking1>
    <masking2>False</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>9/12/1998</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <postcode>4029</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Clare Boothroyd</primarysponsorname>
    <primarysponsoraddress>Suite 9a, Administrative Building
Greenslopes Private Hospital
Newdegate street
Greenslopes
QLD, 4120</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Queensland</fundingname>
      <fundingaddress>UQ Campus, St Lucia, Brisbane, Queensland, 4067</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Georgia Heathcote</sponsorname>
      <sponsoraddress>3/396 Scarborough Road,
Scarborough
QLD, 4020</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study was approved in 1998 by the Royal Brisbane Human Research Ethics Committee.  </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Georgia Heathcote</name>
      <address>3/396 Scarborough Road,
Scarborough
QLD, 4020</address>
      <phone>+61 0447577910</phone>
      <fax />
      <email>georgia.heathcote@gmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Georgia Heathcote</name>
      <address>3/396 Scarborough Road,
Scarborough
QLD, 4020</address>
      <phone>+61 0447577910</phone>
      <fax />
      <email>georgia.heathcote@gmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Georgia Heathcote</name>
      <address>3/396 Scarborough Road,
Scarborough
QLD, 4020</address>
      <phone>+61 0447577910</phone>
      <fax />
      <email>georgia.heathcote@gmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Clare Boothroyd</name>
      <address>Suite 25, level 1
Greenslopes Specialist Centre
Newdegate Street,
Greenslopes
Brisbane
QLD,  4120</address>
      <phone>+61 07 3394 4108 	</phone>
      <fax />
      <email>fertility@ivfmed.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>